Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference


/* Style Definitions */
span.prnews_span
{
font-size:8pt;
font-family:"Arial";
color:black;
}
a.prnews_a
{
color:blue;
}
li.prnews_li
{
font-size:8pt;
font-family:"Arial";
color:black;
}
p.prnews_p
{
font-size:0.62em;
font-family:"Arial";
color:black;
margin:"0in";
}










Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference

PR Newswire











COLUMBIA, Md. and TORONTO, May 22, 2013 /PRNewswire/ -- Medifocus, Inc. (OTCQX: MDFZF and TSXV: MFS)  announced today that John Mon, Chief Operating Officer, will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel.




The Company's presentation is scheduled to begin at 4:00 p.m. EDT and will be available via a live webcast. To access the webcast, go to:  http://wsw.com/webcast/marcum/mfs.v/ 




For more information and registration, please visit the conference website: http://www.marcumllp.com/microcap




About Medifocus, Inc.




Medifocus develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia ("BPH"). With the recent acquisition of Prolieve®, Medifocus now owns a revenue generating commercial BPH treatment product targeting the much larger BPH drug therapy market and generating cash flow to support the development and commercialization of other catheter based or Adaptive Phased Array (APA) based focused heat systems for targeted thermotherapy of surface, subsurface and deep seated localized and regional cancers.




The Company owns two technology platforms with comprehensive US and international patent protection: 1: The Endo-thermotherapy Platform-from which Prolieve was developed can potentially used to treat cancers in prostate, rectal, cervical and esophageal, and 2: The Adaptive Phased Array (APA) Microwave Focusing Platform-invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, is currently in pivotal Phase-III clinical trials. Please visit www.medifocusinc.com, www.prolieve.com.




About Marcum LLP




Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partners, in more than 20 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus Partners LLC.




Investor or Corporate Contacts:
Medifocus, Inc.

Augustine Cheung. President and CEO
410-290-5734

acheung@medifocusinc.com



SOURCE Marcum LLP











Medifocus (CE) (USOTC:MDFZF)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Medifocus (CE) Charts.
Medifocus (CE) (USOTC:MDFZF)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Medifocus (CE) Charts.